Raquel Luque

999 total citations
35 papers, 491 citations indexed

About

Raquel Luque is a scholar working on Pulmonary and Respiratory Medicine, Genetics and Oncology. According to data from OpenAlex, Raquel Luque has authored 35 papers receiving a total of 491 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 15 papers in Genetics and 13 papers in Oncology. Recurrent topics in Raquel Luque's work include Glioma Diagnosis and Treatment (15 papers), Prostate Cancer Treatment and Research (9 papers) and Radiopharmaceutical Chemistry and Applications (6 papers). Raquel Luque is often cited by papers focused on Glioma Diagnosis and Treatment (15 papers), Prostate Cancer Treatment and Research (9 papers) and Radiopharmaceutical Chemistry and Applications (6 papers). Raquel Luque collaborates with scholars based in Spain, Switzerland and Italy. Raquel Luque's co-authors include José Prados, Consolación Melguizo, Raúl Ortíz, Laura Cabeza, Gloria Perazzoli, Cristina Jiménez‐Luna, Miguel Gil‐Gil, Maria Martinez‐García, Carmen Balañá and Juan Manuel Sepúlveda-Sánchez and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Raquel Luque

31 papers receiving 487 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Raquel Luque Spain	11	204	173	125	119	103	35	491
Sei Sai South Korea	12	70 0.3×	203 1.2×	159 1.3×	128 1.1×	137 1.3×	25	492
Francois J. Geoffroy United States	9	234 1.1×	204 1.2×	180 1.4×	109 0.9×	285 2.8×	18	571
Ekatherine Asatiani United States	10	102 0.5×	360 2.1×	101 0.8×	60 0.5×	120 1.2×	19	659
Haishi Zhang China	10	92 0.5×	193 1.1×	36 0.3×	88 0.7×	106 1.0×	18	362
E. Ruth Plummer United Kingdom	13	57 0.3×	229 1.3×	74 0.6×	94 0.8×	210 2.0×	20	470
Enqi Qiao China	14	48 0.2×	203 1.2×	64 0.5×	146 1.2×	93 0.9×	25	475
Jason M. Beckta United States	10	108 0.5×	366 2.1×	59 0.5×	76 0.6×	195 1.9×	27	544
John Latigo United Kingdom	8	67 0.3×	257 1.5×	89 0.7×	126 1.1×	138 1.3×	9	546
Buhai Wang China	13	58 0.3×	239 1.4×	245 2.0×	185 1.6×	269 2.6×	41	630
Lotte Hiddingh United States	8	97 0.5×	214 1.2×	88 0.7×	109 0.9×	203 2.0×	9	523

Countries citing papers authored by Raquel Luque

Since Specialization

Citations

This map shows the geographic impact of Raquel Luque's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Raquel Luque with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Raquel Luque more than expected).

Fields of papers citing papers by Raquel Luque

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Raquel Luque. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Raquel Luque. The network helps show where Raquel Luque may publish in the future.

Co-authorship network of co-authors of Raquel Luque

This figure shows the co-authorship network connecting the top 25 collaborators of Raquel Luque. A scholar is included among the top collaborators of Raquel Luque based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Raquel Luque. Raquel Luque is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Arija, Jóse Ángel Arranz, Xavier García del Muro, Raquel Luque, et al.. (2024). SEOM-GG clinical guidelines for the management of germ-cell testicular cancer (2023). Clinical & Translational Oncology. 26(11). 2783–2799. 4 indexed citations

Salgado, María Ángeles Vaz, et al.. (2024). SEOM-GEINO clinical guidelines for grade 2 gliomas (2023). Clinical & Translational Oncology. 26(11). 2856–2865. 1 indexed citations

Garrigós, Carmen, Javier Puente, B. Mellado González, et al.. (2022). Single-Nucleotide Polymorphism Associations with Efficacy and Toxicity in Metastatic Castration-Resistant Prostate Cancer Treated with Cabazitaxel. Pharmacogenomics. 23(11). 627–638. 1 indexed citations

Luque, Raquel, Manuel Benavides, Sonia Del Barco, et al.. (2021). SEOM clinical guideline for management of adult medulloblastoma (2020). Clinical & Translational Oncology. 23(5). 940–947. 7 indexed citations

Ortíz, Raúl, Gloria Perazzoli, Laura Cabeza, et al.. (2020). Temozolomide: An Updated Overview of Resistance Mechanisms, Nanotechnology Advances and Clinical Applications. Current Neuropharmacology. 19(4). 513–537. 115 indexed citations

Estival, Anna, Carolina Sanz, José Luis Ramírez, et al.. (2019). Pyrosequencing versus methylation-specific PCR for assessment of MGMT methylation in tumor and blood samples of glioblastoma patients. Scientific Reports. 9(1). 11125–11125. 28 indexed citations

Carles, Joan, Enrique Gallardo, Montserrat Domènech, et al.. (2018). Phase 2 Randomized Study of Radiation Therapy and 3-Year Androgen Deprivation With or Without Concurrent Weekly Docetaxel in High-Risk Localized Prostate Cancer Patients. International Journal of Radiation Oncology*Biology*Physics. 103(2). 344–352. 5 indexed citations

Martinez‐García, Maria, Cristina Carrato, L. Ley, et al.. (2017). SEOM clinical guidelines for diagnosis and treatment of glioblastoma (2017). Clinical & Translational Oncology. 20(1). 22–28. 54 indexed citations

Sepúlveda-Sánchez, Juan Manuel, María Ángeles Vaz Salgado, Carmen Balañá, et al.. (2017). Phase II trial of dacomitinib, a pan–human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification. Neuro-Oncology. 19(11). 1522–1531. 85 indexed citations

10.

Molina, David, Julián Pérez-Beteta, Alicia Martínez‐González, et al.. (2016). Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma Patients. PLoS ONE. 11(8). e0161484–e0161484. 10 indexed citations

11.

Teixidor, Pilar, Gerard Plans, Santiago Medrano, et al.. (2016). Results of a multicenter survey showing interindividual variability among neurosurgeons when deciding on the radicality of surgical resection in glioblastoma highlight the need for more objective guidelines. Clinical & Translational Oncology. 19(6). 727–734. 7 indexed citations

12.

Puente, Javier, Aranzazu González del Alba, Núria Sala, et al.. (2016). Novel agents’ sequencing following first-line docetaxel in mCRPC patients: CAPRO study.. Journal of Clinical Oncology. 34(2_suppl). 229–229. 1 indexed citations

13.

Prados, José, Laura Cabeza, Raúl Ortíz, et al.. (2015). Enhanced antitumor activity of doxorubicin in breast cancer through the use of poly(butylcyanoacrylate) nanoparticles. International Journal of Nanomedicine. 10. 1291–1291. 58 indexed citations

14.

Gómez-Río, Manuel, et al.. (2015). 18F-Fluorocholine PET/CT as a complementary tool in the follow-up of low-grade glioma: diagnostic accuracy and clinical utility. European Journal of Nuclear Medicine and Molecular Imaging. 42(6). 886–895. 16 indexed citations

15.

Sepúlveda-Sánchez, Juan Manuel, María Ángeles Vaz Salgado, Marta Gil, et al.. (2015). 2902 GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of Dacomitinib, a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutation. European Journal of Cancer. 51. S585–S585. 1 indexed citations

16.

Sepúlveda-Sánchez, Juan Manuel, María Ángeles Vaz Salgado, Aurelio Hernández‐Laín, et al.. (2014). GEINO-11: A prospective multicenter, open label, phase II pilot clinical trial to evaluate safety and efficacy of PF-299804 (dacomitinib), a pan-HER irreversible inhibitor, in patients with recurrent glioblastoma with EGFR amplification or presence of EGFRvIII mutation.. Journal of Clinical Oncology. 32(15_suppl). TPS2110–TPS2110. 1 indexed citations

17.

Melguizo, Consolación, José Prados, Raquel Luque, et al.. (2012). Modulation of multidrug resistance gene expression in peripheral blood mononuclear cells of lung cancer patients and evaluation of their clinical significance. Cancer Chemotherapy and Pharmacology. 71(2). 537–541. 10 indexed citations

18.

Melguizo, Consolación, José Prados, Raquel Luque, et al.. (2012). Modulation of MDR1 and MRP3 Gene Expression in Lung Cancer Cells after Paclitaxel and Carboplatin Exposure. International Journal of Molecular Sciences. 13(12). 16624–16635. 20 indexed citations

19.

Balañá, Carmen, Óscar Gallego, José María Viéitez, et al.. (2011). Phase II randomized study of preradiation treatment with temozolomide (TMZ) and bevacizumab (BEV) previous to TMZ plus radiation plus BEV versus the same treatment without BEV therapy in unresectable glioblastoma (GB): GENOM 009.. Journal of Clinical Oncology. 29(15_suppl). e12519–e12519.

20.

González‐Flores, Encarnación, et al.. (2009). Biochemotherapy in the treatment of metastatic melanoma in selected patients. Clinical & Translational Oncology. 11(6). 382–386. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact